Meklēšana Attēli Maps Play YouTube Ziņas Gmail Disks Vēl »
Ieiet
Grāmatas Grāmatas
" Pharmaceutical R&D is a risky investment; therefore, high financial returns are necessary to induce companies to invest in researching new chemical entities. Changes in Federal policy that affect the cost, uncertainty and returns of pharmaceutical R&D... "
Legislative Branch Appropriations for 1995: Hearings Before a Subcommittee ... - 388. lappuse
autors: United States. Congress. House. Committee on Appropriations. Subcommittee on Legislative, United States. Congress. House. Committee on Appropriations. Subcommittee on Legislative Appropriations - 1994
Pilnskats - Par šo grāmatu

Health Security Act of 1993: Hearings Before the Committee on Labor ..., 3. daļa

United States. Congress. Senate. Committee on Labor and Human Resources - 1993 - 362 lapas
...in the capital markets to attract financing. The Office of Technology Assessment ("OTA") explained, Pharmaceutical R&D is an investment, and the principal...careful consideration of the effects on R&D is needed." It is fair to ask why pension funds, institutions and other investors would assume more risk by investing...
Pilnskats - Par šo grāmatu

Health Security Act of 1993: Hearings Before the Committee on Labor ..., 3. daļa

United States. Congress. Senate. Committee on Labor and Human Resources - 1993 - 364 lapas
...in the capital markets to attract financing. The Office of Technology Assessment ("OTA") explained, Pharmaceutical R&D is an investment, and the principal...changes, careful consideration of the effects on R&D is needed.1 It is fair to ask why pension funds, institutions and other investors would assume more risk...
Pilnskats - Par šo grāmatu

Health Care Reform and the Role of Medical Technologies: Hearing ..., 4. sējums

United States. Congress. House. Committee on Science, Space, and Technology. Subcommittee on Technology, Environment, and Aviation - 1993 - 114 lapas
...editorial in the April 2, 1993 issue of Science states. Drug development is both expensive and risky. "Pharmaceutical R&D is a risky investment; therefore,...companies to invest in researching new chemical entities,' the Office of Technology Assessment stated In a 1993 report. "Specific policies of US and other governments...
Pilnskats - Par šo grāmatu

Health Care Reform: Expansion of Medicare benefits to include prescription ...

United States. Congress. House. Committee on Ways and Means. Subcommittee on Health - 1993 - 420 lapas
...development." •Pharmaceutical R6D Is a risky investment,' the OTA stated In Its February 1993 report. "Therefore, high financial returns are necessary to...Induce companies to Invest In researching new chemical entitles." The OTA study focuses In large part on drugs approved by FDA In the early 1960s, and on...
Pilnskats - Par šo grāmatu

Legislative Branch Appropriations for Fiscal Year 1995: Hearings Before a ...

United States. Congress. Senate. Committee on Appropriations. Subcommittee on the Legislative Branch - 1994 - 442 lapas
...PUBLICATIONS PRINTED AND DELIVERED IN FISCAL YEAR 1993 Pharmaceutical R&D: Costs, Risks, and Rewards Pharmaceutical costs are among the fastest growing...careful consideration of the effects on R&D is needed. Drug Labeling in Developing Countries This report evaluates the prescribing information — "labeling"...
Pilnskats - Par šo grāmatu

Legislative Branch Appropriations for Fiscal Year 1995: Hearings Before a ...

United States. Congress. Senate. Committee on Appropriations. Subcommittee on the Legislative Branch - 1994 - 428 lapas
...PUBLICATIONS PRINTED AND DELIVERED IN FISCAL YEAR 1993 Pharmaceutical R&D: Costs, Risks, and Rewards Pharmaceutical costs are among the fastest growing...careful consideration of the effects on R&D is needed. Drug Labeling in Developing Countries This report evaluates the prescribing information — "labeling"...
Pilnskats - Par šo grāmatu

Pharmaceutical R&D: Costs, Risks and Rewards : Summary, 49. lapa

1993 - 380 lapas
...health of Americans, for health care costs, and for the future of the US pharmaceutical industry. OTA's report focuses mainly on the economic side of the...careful consideration of the effects on R&D is needed. The specific request for this study came from the House Committee on Energy and Commerce and its Subcommittee...
Pilnskats - Par šo grāmatu

Health Security Act of 1993: Hearings Before the Committee on Labor ..., 3. daļa

United States. Congress. Senate. Committee on Labor and Human Resources - 1993 - 358 lapas
...investment, and the principal characteristic of an investment is that money is spent today in the hopes or generating even more money in the future. Pharmaceutical...changes, careful consideration of the effects on R&D is needed.8 It is fair to ask why pension funds, institutions and other investors would assume more risk...
Pilnskats - Par šo grāmatu

Health Care Reform: Hearings Before the Subcommittee on Health of the ...

United States. Congress. House. Committee on Ways and Means. Subcommittee on Health - 1993 - 428 lapas
...development." •Pharmaceutical R&D is a risky investment,* the OTA stated in its February 1993 report. "Therefore, high financial returns are necessary to...companies to invest in researching new chemical entities." The OTA study focuses in large part on drugs approved by FDA in the early 1960s, and on market conditions...
Pilnskats - Par šo grāmatu

Legislative Branch Appropriations, Fiscal Year 1996

United States. Congress. Senate. Committee on Appropriations. Subcommittee on the Legislative Branch - 1995 - 708 lapas
...HIV prevention by the CDC. Fiscal Year 1993 Pharmaceutical R&D: Costs, Risks, and Rewards $312,847 Pharmaceutical costs are among the fastest growing...careful consideration of the effects on R&D is needed. Requested by: House Committee on Energy and Commerce Hon. John D. Dingell, Chairman Hon. Henry A. Waxman,...
Pilnskats - Par šo grāmatu




  1. Mana bibliotēka
  2. Palīdzība
  3. Izvērstā grāmatu meklēšana
  4. Lejupielādējiet ePub
  5. Lejupielādēt PDF